BCL2 and B-cell chronic lymphocytic leukemia: Recently, ibrutinib19,20, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax21,22, a selective BCL2 inhibitor have been approved for CLL treatment.